Human Malignancies

1. Front Matter

   Pages I-XI

   PDF

2. Diagnosis

   1. Front Matter

      Pages 1-1

      PDF

   2. DNA Analysis as a Tool for Determination of Clonality and Lineage in Acute Leukaemias

      • T. L. J. Boehm

      Pages 3-10

   3. Differentiation of the Major Human Tumor Groups Using Monoclonal Antibodies Specific for Individual Intermediate Filament Proteins

      • M. Altmannsberger, H.-P. Fischer, M. Osborn

      Pages 11-26

   4. Serological Diagnosis of Neoplastic Diseases

      • U. Blum, M. Lorenz, D. Drahovsky

      Pages 27-34

   5. Macrophages in the Stroma of Malignant Tumors

      • H. Müller, H. J. Stutte

      Pages 35-45

   6. Biological Markers in the Classification and Diagnosis of Disorders of the Human Breast

      • A. M. Neville

      Pages 46-55

3. Therapy

   1. Front Matter

      Pages 57-57

      PDF

   2. Advances in the Chemotherapeutic Treatment of Childhood Leukemia

      • B. Kornhuber

      Pages 59-65

   3. Coexpression of Interleukin 2 and HTLY III Messenger RNA in Patients with Acquired Immune Deficiency Syndrome

      • K. W. Sykora, N. Riedel, J. E. Kolitz, R. Mertelsmann

      Pages 66-79

   4. New Approaches to Cancer Immunotherapy

      • R. A. Reisfeld

      Pages 80-91

   5. Functional Properties and Application of Ganglioside Antibodies to Patients with Malignant Melanoma

      • W. G. Dippold, H. Bernhard, H. P. Dienes, K.-H. Meyer zum Büschenfelde

      Pages 92-97

   6. Therapeutic Application of Iodine-131 Labelled Monoclonal Anti-CEA/CA 19-9, and OC 125 Antibodies

      • R. P. Baum, G. Hör

      Pages 98-118

   7. Metaiodobenzylguanidine in Diagnosis and Treatment of Childhood Neuroblastoma

      • D. Schwabe, F. Maul, V. Gerein, J. Happ, G. Hör, B. Kornhuber

      Pages 119-131

   8. Successful Application of a Virus-Modified Tumor Vaccine for Anti-Metastatic Cancer Immunotherapy

      • V. Schirrmacher

      Pages 132-142

   9. Closing Remarks

      • R. A. Reisfeld

      Pages 143-145

4. Back Matter

   Pages 147-149

   PDF

To scientists, oncology means research on the disease of cancer. The connection between basic research and clinical oncology, however, is not always very clear. Basic research sometimes appears to be an art that is practiced for its own sake and admired for its perfection. The clinician wishes to interpret the issues addressed by basic research, as he is eager to obtain answers to the questions that clinical oncology leaves open. These are, among others, questions as to the etiology and pathogenesis of neoplasma in human beings. In spite of all the technological advances during the past 10 years, the guidelines for new treatments of human leukemias and tumors are still unsatisfactory. The dialogue between researchers and clinicians must never cease, so that these questions can be formulated in such a way that science may be able to answer them. Both parties should cooperate whenever this is useful and possible. Prospectively planned clinical trials on the diagnosis and therapy of neoplasias offer a good opportunity for research involving patients. Tumor and/or blood tests run by reference laboratories on a great number of patients with the same diagnosis can lead to clinically relevant basic research. Using clinical studies in basic research programs permits us to trace missing pieces in the puzzle of cancer and put them into place.

• DNA
• childhood
• classification
• diseases
• imaging
• immunotherapy
• infection
• infections
• leukemia
• macrophages
• melanoma
• proteins
• tumor
• vaccine

• Zentrum der Biologischen Chemie, Universität Frankfurt, Frankfurt/Main 70, Germany

  D. Drahovsky

• Zentrum der Kinderheilkunde, Klinikum der Universität Frankfurt, Frankfurt/Main 70, Germany

  B. Kornhuber

Policies and ethics